Michael Schmitz

Stock Analyst at Guggenheim

(2.62)
# 2,166
Out of 5,044 analysts
9
Total ratings
66.67%
Success rate
14.81%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Michael Schmitz

Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $109$97
Current: $94.89
Upside: +2.22%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $29.13
Upside: +47.61%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $40.08
Upside: +12.29%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72$82
Current: $58.17
Upside: +40.97%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $9.50
Upside: +321.05%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -